biotech · Chronic Inducible Urticaria · Chronic Spontaneous Urticaria · JSPR
Jasper Therapeutics
Jasper Therapeutics is a biotech organization headquartered in Redwood City, USA. It trades on NYSE under ticker JSPR. Primary therapeutic focus areas include Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, a
Redwood City, CA, US HQ
44 Employees
Public company Type
JSPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Redwood City, CA, US
- Employees
- 44
- Programs
- 13
- Drugs
- 13
- Patents
- 1
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Phase 2 · mab · SCID
Humanized anti-CD117 Monoclonal Antibody (JSP191) for SCID is a Phase 2 program (mab) at Jasper Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code JAS-BMT-CP-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jasper Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- SCID
- Status
- terminated
- Trials
- 1